San Jose, CA, February 1, 2024
Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-931, which is poised for Phase 2/3 clinical trials. NA-931 is a small molecule drug available in oral formulation.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-931, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, which the Company is in licensing discussions.
It has been found that NA-931 can significantly reduce the body mass index, without causing the muscle loss
“We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-931 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial”, said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued “We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments.”
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease and other neurological disorders. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
For more news, please visit our News pages.
For further information about Biomed Industries, Inc., please contact us.